Crotyl Isocyanate. To a suspension of 41.54 g (0.256 mole) of 1,1'-carbonyldiimidazole in 100 ml of CH₄Cl₄ was slowly added, with stirring during 0.5 hr at 25°, 18.0 g (0.256 mole) of crotylamine. After standing overnight, the solution was slowly distilled through an 18-cm, glass-helices-packed, column. After removing the CH₄Cl₂, a fraction boiling at 45-46° (56 mm) was collected. This was redistilled at atmospheric pressure yielding 9.7 g (39.9%) of colorless liquid, bp 113°. Ir and nmr support the structure, and gc indicates it was greater than 94.7% pure. Christophersen and Holm⁴ report bp 116°.

Cyclopropyl Isocyanate. A suspension of 35.8 g (0.55 mole) of NaN₃ in 200 ml of triethylene glycol dimethyl ether in a 1-1, flask fitted with a stirrer, thermometer, dropping funnel, and a Vigreux column to which was attached a Dry Ice cooled, two-necked flask was cooled to 5°, and 52.25 g (0.5 mole) of cyclopropylcarbonyl chloride was slowly added under N₂ during 10 min. After stirring at 0-25° for 1 hr, the mixture was slowly heated in a water bath. At about 55° N₂ started to come off and it was evolved rapidly at 70-103°. The flask was then heated in an oil bath up to 171°, and the product was distilled at 56 mm. Solvent refluxed in the bottom of the column. The distillate was redistilled through an 18-cm, glass-helices-packed column giving 25.67 g (62%) of colorless liquid, bp 87° (atm), n^{26} D 1.4210; d_4^{25} 1.00. Jones and Scott⁵ apparently prepared this but did not isolate or characterize it.

Acknowledgments. The authors wish to thank the following people who contributed to this work: our Physical and Analytical Chemistry Unit for analytical and spectral data; Mr. Bharat V. Kamdar and Mr. Walter Friis for technical assistance.

References


- (1) R. B. Moffett and A. D. Rudzik, J. Med. Chem., 14, 588 (1971). (paper 9).
- (2) L. H. Sternback, L. O. Randall, R. Banziger, and H. Lehr, "Drugs Affecting the Central Nervous System," Vol. 2, A. Burger, Ed., Marcel Dekker, New York, N.Y., 1968, Chapter 6, p 252.
- (3) Y. Usui, Y. Hara, I. Mikami, and T. Asuda, *Takeda Kenkyusho* Nempo, 30, 145 (1971).
- (4) C. Christophersen and A. Holm, Acta Chem. Scand., 24, 1852 (1970).
- (5) L. W. Jones and A. W. Scott, J. Amer. Chem. Soc., 44, 407 (1922).
- (6) G. H. Youngdale, D. G. Anger, W. C. Anthony, J. P. Da Vanzo, M. E. Greig, R. V. Heinzelman, H. H. Keasling, and J. Szmuszkovicz, J. Med. Chem., 7, 415 (1964).
- (7) H. H. Keasling, E. L. Schumann, and W. Veldkamp, *ibid.*, 8, 548 (1965).
- (8) J. B. Hester, A. D. Rudzik, and B. V. Kamdar, *ibid.*, 14, 1078 (1971).
- (9) J. B. Hester, A. D. Rudzik, H. H. Keasling, and W. Veldkamp, *ibid.*, 13, 23 (1970).

Derivatives of Indole-1-acetic Acid as Antiinflammatory Agents

Karl J. Doebel* and Jan W. F. Wasley

Research Department, Pharmaceuticals Division, Ciba-Geigy Corporation, Ardsley, New York 10502. Received January 7, 1972


In view of the activity of 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid (1, Indomethacin) as an antiinflammatory agent, a study of molecular models showed 2 to be spatially similar to Indomethacin (1). The related isomer 3 was sufficiently similar to merit investigation also.




The publication of 2^1 prompts us to report our findings in this area.

Results and Discussion

Preparation of 2 and 3 proceeded by similar routes, but for 2 the indole 4a was required. This was prepared by catalytic hydrogenation of 5.




The general synthetic pathway involved the condensation of p-chlorobenzonitrile with 4a or 4b to yield the imines 6a and 6b, respectively. It was anticipated that the imines would readily hydrolyze to the corresponding ketones 7a and 7b, but this was not the case.



Alkylation of 6a or 6b with ethyl bromoacetate in acetone in the presence of anhydrous K_2CO_3 proceeded smoothly, and alkaline hydrolysis (3 N NaOH) of the intermediate esters gave the desired products 2 and 3.

A comparison of the pK_{mcs} and distribution coefficients indicated that 2 and 3 are significantly more acidic than Indomethacin (1), as can be seen from Table I.

In order to obtain molecules with acidity similar to indomethacin (1), the corresponding 1-propionic and 1-isobutyric acid derivatives 8 and 9 were prepared by the con-



densation of **6b** with methyl acrylate and methyl methacrylate, respectively, followed by alkaline hydrolysis of the intermediate esters. As can be seen from Table I, the acidity of these compounds now approximates that of 1.

Table I		
Compound	pK _{mcs}	P (CHCl ₃ -aqueous buffer, pH 6.9)
1	6.45	37.2
2	4.97	0.13
3	5.00	0.13
8	6.08	11.9
9	6.26	60.0

Biological Activity. Antiinflammatory tests were performed on compounds 2, 3, 8, and 9 using the uv erythema screen² (guinea pigs) and anticarrageenin (rat paw edema) screen.³

Compounds 2 and 3 were inactive in these screens. Compounds 8 and 9 showed marginal activity in the anticarrageenin screen, 14 and 12%, respectively, at 100 mg/kg po, and 9 exhibited 44% inhibition in the uv erythema test at 100 mg/kg po.

By comparison 1 caused 39 and 48% inhibition in the anticarrageenin screen at doses of 2 and 4 mg/kg po, respectively. In the uv test 1 exhibited 58% inhibition at a dose of 4 mg/kg po.

Experimental Section[†]

3-Nitro-4-(2-nitropropenyl)anisole (5). This was prepared from 2-nitroanisaldehyde⁵ (10 g) and nitroethane (7 ml) by the method of Beer, *et al.*⁶ The product crystallized from ethanol as long yellow needles (5.5 g, 38.3%), mp $109-110^{\circ}$.

6-Methoxy-2-methyllindole (4a). To 3-nitro-4-(2-nitropropenyl)an; sole (5 g, 0.02 mole) in glacial AcOH (125 ml) and EtOH (125 ml) was added 5% Pd/C (1 g), and the mixt was hydrogenated at atm pressure and room temp until 6 mole equiv of H_2 was absorbed. The catalyst was filtered, and the filtrate neutralized with NaHCO₃ in the presence of Et₂O. The neutralized soln was further extracted with Et₂O (3 × 500 ml), dried (Na₂CO₃), and evapd to yield a pale green solid. This was purified by Soxhlet extraction with petr ether (bp 60-80°), yielding colorless prisms (2.5 g, 75%), mp 102-103° (lit.⁷ 102-103°).

3-p-Chlorobenzimidoyl-6-methoxy-2-methylindole (6a). Crude 6-methoxy-2-methylindole (7.5 g, 0.046 mole) and p-chlorobenzonitrile (18.8 g, 0.14 mole) were dissolved in 50 ml of Et₂O. Anhydrous HCl was bubbled through the soln for 8 hr. A solid pptd initially, then redissolved after about 2 hr. After 5 hr, a solid again began to separate. The reaction flask was stoppered and stored at 5° for 5 days. The Et₂O was decanted, fresh Et₂O (100 ml) was added, and the mixt was stirred for 1 hr. The imine HCl was removed by filtration, dried *in vacuo*, dissolved in hot EtOH, and basified (pH 9) with 10% NH₄OH. The product crystd from CHCl₃petr ether as off-white prisms (2.5 g, 17%), mp 204-205°. Anal. (C₁₇H₁₅ClN₂O) N.

3-p-Chloro benzoyl-6-methoxy-2-methylindole-1-acetic Acid (2). A mixt of 3-p-chloro benzimidoyl-6-methoxy-2-methylindole (5.25 g, 0.017 mole), ethyl bromoacetate (3.3 g, 0.02 mole), reagent grade Me₂CO (30 ml), and anhyd K₂CO₃ (16 g) was heated under reflux for 18 hr. After cooling, the solid was filtered and washed well with Me₂CO (250 ml). The filtrates were evapd yielding a brown oily residue (\simeq 5 g), which was heated under reflux with 3 N NaOH (75 ml) for 2 hr. The Na salt of 2 was crystd from the mixt, collected by filtration, and dissolved in hot H₂O (1 1.), and the soln filtered to remove the insol by-product 7a. Acidification of the filtrate with 10% H₂SO₄ yielded a pale yellow ppt which was collected, dried *in vacuo*, and then crystd from EtOH as pale yellow needles (1.5 g, 25%), mp 237-238°. Anal. (C₁₉H₁₆CINO₄) C, H, N, CI.

3-p-Chlorobenzimidoyl-5-methoxy-2-methylindole (6b). This was prepared in a manner analogous to 3-p-chlorobenzimidoyl-6-methoxy-2-methylindole (6a). The product crystd from aqueous EtOH as colorless needles (43%), mp 190-192°. Anal. ($C_{17}H_{15}ClN_2O$) C, H, N, Cl.

3-p-Chlorobenzoyl-5-methoxy-2-methylindole-1-acetic Acid (3). This was prepared in a manner analogous to 3-p-chlorobenzoyl-6-methoxy-2-methylindole-1-acetic acid (2). The product crystd from EtOH as colorless needles (33%), mp 248-249°. Anal. $(C_{19}H_{16}CINO_4)$ C, H, N, Cl.

3-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-1-propionic Acid (8). 3-p-Chlorobenzimidoyl-5-methoxy-2-methylindole (5.0 g, 0.017 mole), methyl acrylate (1.7 g, 0.017 mole), Me₂CO (150 ml), and anhyd K₂CO₃ (1.0 g) were combined and heated under reflux for 72 hr. On cooling, the solid was filtered and washed well with Me₂CO (100 ml). The combined filtrates were evapd to yield a brown oily residue, which was heated under reflux with 3 N NaOH (50 ml) until a homogenous soln was obtained (~2 hr). On cooling, a white ppt formed (Na salt), which was collected by filtration, dissolved in hot H₂O (750 ml), and acidified (pH 2) with 10% H₂SO₄. The product was collected, dried *in vacuo*, and crystd from EtOH as colorless needles (3.6 g, 58%). Anal. (C₂₀H₁₅CINO₄) C, H, N, Cl.

3-(p-Chlorobenzoyl)-5-methoxy- α ,2-dimethylindole-1-propionic Acid (9). 3-p-Chlorobenzimidoyl-5-methoxy-2-methylindole (5.0 g, 0.017 mole) and methyl methacrylate (10 g, 0.1 mole) reacted under conditions similar to those for 8. The product was recrystd from EtOH as pale yellow needles (400 mg, 6.2%), mp 178-179°. Anal. ($C_{21}H_{20}CINO_4$) C, H, N, Cl.

Acknowledgments. We wish to express our appreciation to Mrs. M. L. Graeme and coworkers for the antiinflammatory testing and to Mr. S. Lopoukhine for technical assistance. We are indebted to Mrs. M. Myers and associates for the microanalyses.

References

- (1) Roussel-UCLAF, French Patent 5.173M (1966).
- (2) C. V. Winder, J. Wax, V. Burr, M. Been, and C. E. Rosiere, Arch. Int. Pharmacodyn., 116, 261 (1958).
- (3) C. A. Winter, E. A. Risley, and G. W. Nuss, Proc. Soc. Exp. Biol. Med., 111, 544 (1962).
- (4) W. Simon and E. Heilbronner, Helv. Chim. Acta, 40, 210 (1957).
- (5) R. B. Woodward, F. E. Bader, H. Bickel, A. J. Frey, and R. W. Kierstead, Tetrahedron, 2, 22 (1958).
- (6) R. J. S. Beer, K. Clarke, H. F. Davenport, and A. Robertson, J. Chem. Soc., 2029 (1951).
- (7) E. Spath and O. Brunner, Ber., 58B, 518 (1925).

Some Hypotensive Thiadiazoles[†]

A. M. Grant, S. V. Krees, A. B. Mauger,* W. J. Rzeszotarski, and F. W. Wolff

Research Foundation of the Washington Hospital Center, Washington, D. C. 20010. Received February 10, 1972

In two structurally unrelated series of diuretics it has been observed that removal of the sulfamoyl group results in a loss of diuretic activity and the enhancement of hypotensive activity. Firstly, the diuretic benzothiadiazines² led to the development of diazoxide³ and studies of its analogs.^{4,5} Secondly, various hypotensive phthalimidines^{6,7} related to chlorthalidone⁸ were described. We now report a third series structurally unrelated to the other two, derived from acetazolamide.9 The compounds discussed here, except for some analogous thiazoles, are all related to 2amino-1,3,4-thiadiazole by substitution in the amino group and, in a few cases, in the 5 position. Derivatives of acetazolamide, a powerful carbonic anhydrase inhibitor, have not previously been described as having hypotensive properties. However, it was observed by Rubin, et al., ¹⁰ that "removal of the sulfamoyl group from substances having diuretic properties usually yields compounds lacking diuretic effect but showing antihypertensive activity."

[†]Melting points were determined with a Thomas-Hoover apparatus equipped with a corrected thermometer. Microanalyses were performed by the Analytical Research Department of Geigy Chemical Corp. Where analyses are indicated only by symbols of the elements, analytical results for those elements were within ±0.4% of the theoretical values. pK_{mCS} were determined by the method of Simon and Heilbronner.⁴ Distribution coefficients were detd spectrophotometrically on aqueous buffer solns of the compds equilibrated with CHCl₂.

[†]This project was performed in the George Hyman Memorial Research Building at the Washington Hospital Center and was supported by the Research Foundation of the Washington Hospital Center and by N.I.H. Grant 5RO1 HE12963. A preliminary report of part of this work was given at the National Meeting of the American Federation for Clinical Research, Atlantic City, N. J., May 1970.¹